New study shows promise for repurposing anti-malarial drug for cancer treatment

January 11, 2017 by Allison Perry
UK's Vivek Rangnekar, left, and Ravshan Burikhanov. Credit: University of Kentucky

A new study by University of Kentucky Markey Cancer Center researchers shows that chloroquine – a drug currently used to treat malaria – may be useful in treating patients with metastatic cancers.

Published in Cell Reports, the study showed that chloroquine induced the secretion of the Par-4 in both mouse models and in cancer patients in a clinical trial. Secreted Par-4 is essential for tumor cell death and the inhibition of tumor metastasis.

Chloroquine induces Par-4 secretion via the classical secretory pathway that requires activation of p53 (a mutation of the , or disturbances in the pathways that signal to p53, is common in many cancers). Mechanistically, p53 directly induces Rab8b, a GTPase essential for vesicle transport of Par-4 to the plasma membrane prior to secretion. The study's findings indicate that chloroquine induces p53- and Rab8b-dependent Par-4 secretion from normal cells for Par-4-dependent inhibition of metastatic tumor growth.

The study was led by the lab of Vivek M. Rangnekar, the Alfred Cohen endowed chair in oncology research at the UK Markey Cancer Center and a professor in the UK Department of Radiation Medicine. UK Researchers Ravshan Burikhanov and Nikhil Hebbar in Rangnekar's group were co-first authors in the study.

"Because p53 is often mutated in tumors, it makes the tumors resistant to treatment," said Rangnekar, also the co-leader of the Cancer Cell Biology and Signaling research program and associate director at Markey. "However, this study shows that the relatively safe, FDA-approved drug chloroquine empowered – which express wild type p53 – to secrete Par-4 and stop metastasis in p53-deficient tumors."

At the UK Markey Cancer Center, one clinical trial using chloroquine for Par-4 induction in a variety of is ongoing. Researchers are now planning a second clinical trial that would involve giving a maintenance dose of chloroquine to patients who are in remission, with the hopes of preventing cancer relapse.

Explore further: New study shows promise for preventing therapy resistance in tumor cells

More information: Ravshan Burikhanov et al. Chloroquine-Inducible Par-4 Secretion Is Essential for Tumor Cell Apoptosis and Inhibition of Metastasis, Cell Reports (2017). DOI: 10.1016/j.celrep.2016.12.051

Related Stories

New study shows promise for preventing therapy resistance in tumor cells

January 9, 2014
A new study led by University of Kentucky researchers suggests that activating the tumor suppressor p53 in normal cells causes them to secrete Par-4, another potent tumor suppressor protein that induces cell death in cancer ...

New study identifies molecule that induces cancer-killing protein

September 15, 2014
A new study by University of Kentucky researchers has identified a novel molecule named Arylquin 1 as a potent inducer of Par-4 secretion from normal cells. Par-4 is a protein that acts as a tumor suppressor, killing cancer ...

Bone marrow transplantation may increase cancer resistance in patients

August 24, 2011
Bone marrow transplantation with genetically modified cells may prolong the period of cancer-free survival, suggests a study led by Dr. Vivek Rangnekar, associate director of translational research for the Markey Cancer Center ...

Malaria medicine chloroquine inhibits tumor growth and metastases

August 11, 2014
A recent study by investigators at VIB and KU Leuven has demonstrated that chloroquine also normalizes the abnormal blood vessels in tumors. This blood vessel normalization results in an increased barrier function on the ...

New patent paves way for breast cancer prevention

November 20, 2015
George Mason University researchers have patented a new breast cancer treatment that uses a common malaria drug to stop cancer in its beginning stages.

UK's "super mouse" yielding major discoveries in cancer research

July 26, 2013
It appears tiny and inconsequential enough, but the "super mouse"—created by researchers at the University of Kentucky Markey Cancer Center some six years ago—has spawned plenty of new research into preventing and/or ...

Recommended for you

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

Computer program finds new uses for old drugs

November 16, 2017
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, ...

Pharmacoscopy improves therapy for relapsed blood cancer in a first clinical trial

November 16, 2017
Researchers at CeMM and the Medical University of Vienna presented a preliminary report in The Lancet Hematology on the clinical impact of an integrated ex vivo approach called pharmacoscopy. The procedures measure single-cell ...

Wider sampling of tumor tissues may guide drug choice, improve outcomes

November 15, 2017
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help ...

A new strategy for prevention of liver cancer development

November 14, 2017
Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.